Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PEGFILGRASTIM

All injection strengths: general benefit

Other products in the same Health Canada class (L03AA) — coverage varies; not interchangeable

  • Filgrastim (Nivestym): general benefit

Lapelga · DIN 02474565 · 10mg/mL · injection, pre-filled syringe - 0.6mL Pk (Preservative Free)

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Lapelga · DIN 02474565 Manufacturer: Apotex Inc.; listing date 2019-08-30 Health Canada: Marketed since 2019-02-27 · brand LAPELGA · ATC L03AA13 PEGFILGRASTIM · form Solution · route Subcutaneous · ingredients PEGFILGRASTIM 6 MG/0.6ML · company Apotex inc · schedule Schedule d, Prescription
Check this DIN again · Health Canada product record

Lapelga: Formulary list price $492.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $492.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96479 · Verify on the e-Formulary ↗ (DIN 02474565)

Source record
DIN 02474565: Lapelga Raw flags: sec3=Y Item: 201600054; group id 270; item number 0560; lccId None; manufacturer id APX Source form: Inj Sol-Pref Syr - 0.6mL Pk (Preservative Free); strength: 10mg/mL Recorded listing: General benefit Source prices (unrounded): $492.0000; ministry $492.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02474565 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96479
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (20:16 Hematopoietic Agents) and how they are covered

Matched class: 20:16 Hematopoietic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FILGRASTIM 20:16 Hematopoietic Agents

FILGRASTIM

· 10 products · General benefit · strengths: 300mcg/0.5mL, 480mcg/0.8mL, 480mcg/1.6mL, 300mcg/mL · Inj Sol-0.5mL Pref Syr, Inj Sol-0.5mL Pref Syr (Preservative-Free), Inj Sol-0.8mL Pref Syr, Inj Sol-0.8mL Pref Syr (Preservative-Free), Inj Sol-1.6mL Vial Pk, Inj Sol-1mL Vial Pk, Pref Syr-0.5mL Pk, Pref Syr-0.8mL Pk

DARBEPOETIN ALFA

· 4 products · Limited Use, codes 420 · strengths: 150mcg/0.3mL, 200mcg/0.4mL, 300mcg/0.6mL, 500mcg/1.0mL · Pref Syr-0.3mL Pk, Pref Syr-0.4mL Pk, Pref Syr-0.6mL Pk, Pref Syr-1.0mL Pk

EPOETIN ALFA

· 3 products · Limited Use, codes 420 · strengths: 10,000IU/mL, 40,000IU/mL, 20,000IU/0.5mL · Pref Syr - 1mL Pk, Pref Syr-0.5mL Pk

ELTROMBOPAG OLAMINE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:16
Full class listing Related classes: 20:04 Antianemia Drugs, 20:12 Coagulants and Anti-Coagulants, 20:24 Hemorrheologic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications LAPELGA® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti- neoplastic drugs. 1.1 Pediatrics (< 18 years of age) No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics (> 65 year of age) No data are available to Health Canada; therefore Health Canada has not authorized on indication for geriatric use. https://pdf.hres.ca/dpd_pm/00083321.PDF PM date: 2026-01-29 Source product: LAPELGA; DIN 02474565; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.